| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/31/2002 | WO2002007675A2 Omega-conopeptides |
| 01/31/2002 | WO2002007669A2 Phospholipid derivatives of valproic acid and mixtures thereof |
| 01/31/2002 | WO2001081347A3 Diazabicyclic central nervous system active agents |
| 01/31/2002 | WO2001078580A3 A method combining inducing hypothermia and administering a therapeutic agent |
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001068120A3 Uses of bombesin receptor 3 |
| 01/31/2002 | WO2001062801A3 Humanized antibodies that sequester amyloid beta peptide |
| 01/31/2002 | WO2001062785A3 Protein and gene and their use for diagnosis and treatment of schizophrenia |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001049270B1 Odor-masking coating for a pharmaceutical preparation |
| 01/31/2002 | WO2001043525A3 Method for the preparation of citalopram |
| 01/31/2002 | WO2001039778A3 Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001036605A3 2786, a human aminopeptidase |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013461 Corticotropin releasing factor antagonist |
| 01/31/2002 | US20020013374 Administering compound effective to inhibit binding of an amyloid beta peptide with alpha-7 nicotinic acetylcholine receptors |
| 01/31/2002 | US20020013372 Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| 01/31/2002 | US20020013369 Certain 5-alkyl-2arylaminophenylacetic acids and derivatives |
| 01/31/2002 | US20020013367 For therapy of neoplastic disease |
| 01/31/2002 | US20020013358 Indole derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013356 New polycyclic indanylimidazoles with alpha2 adrenergic activity |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013351 Compounds possessing neuronal activity |
| 01/31/2002 | US20020013349 Administering drug which opens potassium channel for reducing pain |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013342 Useful for treating a central nervous system disorder selected from depression, mood swings, and Alzheimer's disease |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013339 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 01/31/2002 | US20020013336 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |
| 01/31/2002 | US20020013335 Method of treating cardiovascular disease |
| 01/31/2002 | US20020013334 HMG-CoA reductase inhibitors and method |
| 01/31/2002 | US20020013332 Use of nicergoline for treating spasticity |
| 01/31/2002 | US20020013331 For therapy of pain associated with mucosal damage, such as inflamation, abrasions, ulcerations, lesions, incisions, and trauma |
| 01/31/2002 | US20020013330 Providing sedative-hypnotic treatment by administering barbiturate derivative compound |
| 01/31/2002 | US20020013329 For therapy of pain, migraine, depression, anxiety, schizophrenia, Parkinson's disease, stroke, and in therapy of neuropathies including postherpetic neuralgia, central pain from spinal cord injury, and phantom limb pain |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013315 For therapy Alzheimer's disease |
| 01/31/2002 | US20020013313 4,5-dihydro-1,3-dithia-4-aza-acenaphthylene-3,3-dioxide compounds for example; treating ischemia, Alzheimer's disease, schizophrenia; alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) |
| 01/31/2002 | US20020013309 Pharmaceutical compositions and methods for use |
| 01/31/2002 | US20020013301 In an oral dosage form, providing a combination product analgesically effective when administered orally, but which is aversive in addicts at the same dose or higher dose than prescribed; prevention of drug abuse, drug dependency |
| 01/31/2002 | US20020013278 Using an interleukin-1 beta converting enzyme inhibitor pro-drug to treat apoptosis-, interferon-gamma inducing factor or interferon-gamma inducing diseases; antiinflammatory and -proliferative agents; autoimmune/degenerative disesesdiseases |
| 01/31/2002 | US20020013277 Composition and methods to improve neural outcome |
| 01/31/2002 | US20020013270 Administering a microbiocide to inhibit or eliminate at least one symptom of the disorder; also using a probiotic mixture including a replenishing gastrointestinal microbe; anxiolytic agents; autism; psychosis; attention deficit |
| 01/31/2002 | US20020013266 Polymer stabilized neuropeptides |
| 01/31/2002 | US20020013257 Use of ligands to GABAB receptors |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 01/31/2002 | US20020012965 Nucleotide sequences coding prfeerential polypeptides for use in the diagnosis and treatment of brain disorders and injury |
| 01/31/2002 | US20020012906 Method for kidney disease treatment by drug intervention |
| 01/31/2002 | US20020012713 Water-soluble complex of an extract of ginkgo biloba, process for the preparation thereof and composition comprising the same |
| 01/31/2002 | US20020012695 Increased skin permeation of drug, and allows improved drug stability within the adhesive layer |
| 01/31/2002 | US20020012679 Process for manufacturing coated gabapentin or pregabalin particles |
| 01/31/2002 | DE10035144A1 Cyclische Aminosäurederivate Cyclic amino acid derivatives |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | DE10032456A1 Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen Rapidly disintegrating dosage form for the delivery of drugs to the oral cavity or into body cavities |
| 01/31/2002 | CA2417134A1 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2416988A1 Leucine-based motif and clostridial neurotoxins |
| 01/31/2002 | CA2416821A1 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |
| 01/31/2002 | CA2416691A1 Proteases |
| 01/31/2002 | CA2416544A1 Mu-conopeptides |
| 01/31/2002 | CA2416447A1 Novel compounds and their use as glycine transport inhibitors |
| 01/31/2002 | CA2416408A1 Methods for therapy of neurodegenerative disease of the brain |
| 01/31/2002 | CA2416381A1 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 01/31/2002 | CA2416287A1 Omega-conopeptides |
| 01/31/2002 | CA2415742A1 N-substituted indoles useful in the treatment of diabetes |
| 01/31/2002 | CA2415740A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | CA2415606A1 Capsaicin receptor ligands |
| 01/31/2002 | CA2415585A1 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | CA2415362A1 Method for treating fibrotic diseases or other indications |
| 01/31/2002 | CA2415196A1 Cyclic substituted aminomethyl compounds and medicaments comprising these compounds |
| 01/31/2002 | CA2415077A1 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | CA2415054A1 Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging |
| 01/31/2002 | CA2415046A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | CA2412626A1 Il-17 molecules and uses thereof |
| 01/31/2002 | CA2411192A1 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
| 01/30/2002 | EP1176148A1 Benzothiadiazine derivatives, processes for their preparation and pharmaceutical compositions containing them |
| 01/30/2002 | EP1176146A1 Carbamoyl tetrahydropyridine derivatives |
| 01/30/2002 | EP1176144A1 N-triazolylmethyl-piperazine derivatives as neurokinine receptor-antagonists |
| 01/30/2002 | EP1176141A1 HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE $g(a)4$g(b)2 RECEPTOR |
| 01/30/2002 | EP1176138A1 Active derivatives of valproic acid for the treatment of neurological and psychotic disorders and a method for their preparation |
| 01/30/2002 | EP1175909A2 Therapeutic methods and compositions based on serrate proteins and nucleic acids |
| 01/30/2002 | EP1175900A2 Use of growth hormone secretagogues for improvement of fucnctional health status |
| 01/30/2002 | EP1175504A1 Dna encoding the human vanilloid receptor vr1 |
| 01/30/2002 | EP1175503A1 49 human secreted proteins |
| 01/30/2002 | EP1175498A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells |
| 01/30/2002 | EP1175490A2 Tyrosine kinase substrate (tks) proteins |
| 01/30/2002 | EP1175446A1 Human antibodies that bind human il-12 and methods for producing |
| 01/30/2002 | EP1175421A1 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
| 01/30/2002 | EP1175417A1 Substituted benzolactam compounds |
| 01/30/2002 | EP1175416A1 Heteroaryl diazacycloalkanes, their preparation and use |
| 01/30/2002 | EP1175412A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents |
| 01/30/2002 | EP1175409A1 Pyrimidinones derivatives for the treatment of atherosclerosis |
| 01/30/2002 | EP1175408A1 Pyrimidinone compounds |
| 01/30/2002 | EP1175406A1 Imidazoline derivatives as alpha-1a adrenoceptor ligands |
| 01/30/2002 | EP1175401A1 Piperazine derivatives useful as ccr5 antagonists |
| 01/30/2002 | EP1175383A1 Glucocorticoid receptor modulators |